Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Kineta (KA)

Kineta Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KA
DateTimeSourceHeadlineSymbolCompany
07/03/202521:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
06/03/202522:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KAKineta Inc
12/12/202414:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
25/11/202413:48Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KAKineta Inc
25/11/202413:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
08/11/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
08/10/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
08/10/202413:00GlobeNewswire Inc.Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid TumorsNASDAQ:KAKineta Inc
04/10/202413:05GlobeNewswire Inc.Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024NASDAQ:KAKineta Inc
02/10/202420:05GlobeNewswire Inc.Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1NASDAQ:KAKineta Inc
20/09/202401:53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
19/09/202422:23GlobeNewswire Inc.Kineta, Inc Transitioning from Nasdaq to OTC MarketsNASDAQ:KAKineta Inc
19/09/202413:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
13/09/202421:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
05/09/202420:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KAKineta Inc
05/09/202420:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KAKineta Inc
05/09/202420:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KAKineta Inc
05/09/202420:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KAKineta Inc
05/09/202420:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KAKineta Inc
19/08/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
19/08/202413:00PR Newswire (US)TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerNASDAQ:KAKineta Inc
19/08/202413:00GlobeNewswire Inc.Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerNASDAQ:KAKineta Inc
08/08/202420:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KAKineta Inc
08/07/202410:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
08/07/202410:30GlobeNewswire Inc.Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA BiosciencesNASDAQ:KAKineta Inc
30/05/202420:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
15/05/202420:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KAKineta Inc
15/05/202420:01GlobeNewswire Inc.Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate ActivitiesNASDAQ:KAKineta Inc
08/04/202420:01GlobeNewswire Inc.Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialNASDAQ:KAKineta Inc
21/03/202420:02GlobeNewswire Inc.Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:KAKineta Inc
 Showing the most relevant articles for your search:NASDAQ:KA

Your Recent History

Delayed Upgrade Clock